Study of ABT-751 in Patients With Refractory Hematologic Malignancies
NCT00047489
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Hematological Malignancies
Interventions
DRUG:
ABT-751
Sponsor
M.D. Anderson Cancer Center